ID24675A - Turunan-turunan (imidazol-5-il) metil-2-kuinolinona sebagai penghambat proliferasi sel otot halus - Google Patents

Turunan-turunan (imidazol-5-il) metil-2-kuinolinona sebagai penghambat proliferasi sel otot halus

Info

Publication number
ID24675A
ID24675A IDW991506A ID991506A ID24675A ID 24675 A ID24675 A ID 24675A ID W991506 A IDW991506 A ID W991506A ID 991506 A ID991506 A ID 991506A ID 24675 A ID24675 A ID 24675A
Authority
ID
Indonesia
Prior art keywords
sub
sup
alkyl
alkyloxy
hydrogen
Prior art date
Application number
IDW991506A
Other languages
English (en)
Indonesian (id)
Inventor
David William End
Michael J Zelesko
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ID24675A publication Critical patent/ID24675A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW991506A 1997-06-02 1998-05-28 Turunan-turunan (imidazol-5-il) metil-2-kuinolinona sebagai penghambat proliferasi sel otot halus ID24675A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4737697P 1997-06-02 1997-06-02

Publications (1)

Publication Number Publication Date
ID24675A true ID24675A (id) 2000-07-27

Family

ID=21948611

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991506A ID24675A (id) 1997-06-02 1998-05-28 Turunan-turunan (imidazol-5-il) metil-2-kuinolinona sebagai penghambat proliferasi sel otot halus

Country Status (21)

Country Link
US (4) US6365600B1 (cg-RX-API-DMAC10.html)
EP (1) EP0988038B1 (cg-RX-API-DMAC10.html)
JP (1) JP4209472B2 (cg-RX-API-DMAC10.html)
KR (1) KR100517832B1 (cg-RX-API-DMAC10.html)
CN (2) CN100525766C (cg-RX-API-DMAC10.html)
AT (1) ATE222104T1 (cg-RX-API-DMAC10.html)
AU (1) AU740603B2 (cg-RX-API-DMAC10.html)
BR (1) BR9810423A (cg-RX-API-DMAC10.html)
CA (1) CA2290992C (cg-RX-API-DMAC10.html)
DE (1) DE69807222T2 (cg-RX-API-DMAC10.html)
DK (1) DK0988038T3 (cg-RX-API-DMAC10.html)
ES (1) ES2182327T3 (cg-RX-API-DMAC10.html)
ID (1) ID24675A (cg-RX-API-DMAC10.html)
IL (1) IL133212A (cg-RX-API-DMAC10.html)
NO (1) NO318834B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ501401A (cg-RX-API-DMAC10.html)
PT (1) PT988038E (cg-RX-API-DMAC10.html)
RU (1) RU2209066C2 (cg-RX-API-DMAC10.html)
TR (1) TR199902923T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998055124A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA984700B (cg-RX-API-DMAC10.html)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL133212A (en) 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
PT1140935E (pt) * 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
ES2212971T3 (es) 1999-11-30 2004-08-16 Pfizer Products Inc. Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
FR2813791B1 (fr) * 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
US7053105B2 (en) 2000-09-25 2006-05-30 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
WO2002024683A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
ATE409189T1 (de) 2000-09-25 2008-10-15 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体
ES2328225T3 (es) 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
CA2469275C (en) 2001-12-19 2011-09-06 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ES2287466T3 (es) 2002-03-22 2007-12-16 Janssen Pharmaceutica N.V. Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
CA2481480C (en) 2002-04-15 2011-04-12 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US8016881B2 (en) 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US6638301B1 (en) * 2002-10-02 2003-10-28 Scimed Life Systems, Inc. Medical device with radiopacity
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US20050154451A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
BRPI0507076B8 (pt) * 2004-01-23 2021-05-25 Janssen Pharmaceutica Nv quinolinas substituídas, seu processo de preparação, composição farmacêutica que as compreende e seu uso como inibidores micobacterianos
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
US7332605B2 (en) * 2004-03-15 2008-02-19 Anormed, Inc. Process for the synthesis of CXCR4 antagonist
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US7063720B2 (en) * 2004-09-14 2006-06-20 The Wallace Enterprises, Inc. Covered stent with controlled therapeutic agent diffusion
US20060083770A1 (en) * 2004-10-15 2006-04-20 Specialty Coating Systems, Inc. Medical devices and methods of preparation and use
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
WO2006096251A2 (en) 2005-03-03 2006-09-14 Icon Medical Corp. Improved metal alloys for medical device
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
WO2007016525A2 (en) * 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
AU2006331542A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
US20070148390A1 (en) * 2005-12-27 2007-06-28 Specialty Coating Systems, Inc. Fluorinated coatings
ATE547394T1 (de) * 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US8124774B2 (en) * 2007-05-23 2012-02-28 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
CA2860099A1 (en) * 2012-02-13 2013-08-22 Johannes Aebi Imidazolylketone derivatives asd aldosterone synthase inhibitors
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
BR112016030273A8 (pt) 2014-06-24 2021-05-18 Icon Medical Corp dispositivo médico e método para formar o referido dispositivo
US20210322651A1 (en) * 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110204487B (zh) * 2019-06-21 2021-09-28 江南大学 一种喹啉衍生物的合成方法
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
CN113072490B (zh) * 2021-03-26 2022-08-16 中国海洋大学 一种替吡法尼喹啉酮中间体的高效合成方法
CN119371281A (zh) * 2024-12-27 2025-01-28 山东石油化工学院 一种CH2Cl2参与C-H键活化的烷基氯取代的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456347B (sv) 1982-02-09 1988-09-26 Ird Biomaterial Ab Ytmodifierat fast substrat samt forfarande for framstellning derav
US5213898A (en) 1989-10-12 1993-05-25 Norsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5049403A (en) 1989-10-12 1991-09-17 Horsk Hydro A.S. Process for the preparation of surface modified solid substrates
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
JPH07112930A (ja) * 1993-10-14 1995-05-02 Kyowa Hakko Kogyo Co Ltd 血管平滑筋細胞増殖抑制剤
CA2216943C (en) 1995-04-19 2003-06-17 Boston Scientific Limited Drug release coated stent
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69635966T2 (de) * 1995-12-08 2006-11-30 Janssen Pharmaceutica N.V. (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
IL133212A (en) 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells

Also Published As

Publication number Publication date
TR199902923T2 (xx) 2000-11-21
PT988038E (pt) 2002-12-31
NO995883D0 (no) 1999-12-01
IL133212A0 (en) 2001-03-19
US20030229118A1 (en) 2003-12-11
ZA984700B (en) 1999-12-01
HK1025046A1 (en) 2000-11-03
CA2290992A1 (en) 1998-12-10
KR20010012782A (ko) 2001-02-26
ES2182327T3 (es) 2003-03-01
US6743805B2 (en) 2004-06-01
AU8020798A (en) 1998-12-21
DE69807222D1 (de) 2002-09-19
NZ501401A (en) 2002-03-28
KR100517832B1 (ko) 2005-09-30
IL133212A (en) 2005-12-18
CN100525766C (zh) 2009-08-12
JP4209472B2 (ja) 2009-01-14
ATE222104T1 (de) 2002-08-15
JP2002503235A (ja) 2002-01-29
US6365600B1 (en) 2002-04-02
DE69807222T2 (de) 2003-04-17
RU2209066C2 (ru) 2003-07-27
US6734194B2 (en) 2004-05-11
WO1998055124A1 (en) 1998-12-10
AU740603B2 (en) 2001-11-08
NO318834B1 (no) 2005-05-09
US7253183B2 (en) 2007-08-07
CA2290992C (en) 2008-02-12
EP0988038B1 (en) 2002-08-14
BR9810423A (pt) 2000-10-03
CN1231215C (zh) 2005-12-14
EP0988038A1 (en) 2000-03-29
US20040198771A1 (en) 2004-10-07
CN1762355A (zh) 2006-04-26
HK1088820A1 (zh) 2006-11-17
CN1265585A (zh) 2000-09-06
DK0988038T3 (da) 2002-12-02
US20020091138A1 (en) 2002-07-11
NO995883L (no) 2000-02-02

Similar Documents

Publication Publication Date Title
IL133212A0 (en) (Imidazol-5-yl) methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
EP1162201A3 (en) Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
UA50792C2 (uk) 7<font face="Symbol">a</font>-(<font face="Symbol">x</font>-АМІНОАЛКІЛ)ЕСТРАТРИЄНИ ТА ФАРМАЦЕВТИЧНИЙ ПРЕПАРАТ, ЩО ЇХ МІСТИТЬ
Pollack et al. Lack of prostate cancer radiosensitization by androgen deprivation
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
RU2002133868A (ru) Каннабиноидные лекарственные средства
RU2011130526A (ru) Композиции для введения лекарственных средств
RU2000100032A (ru) Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
IL140930A0 (en) Compounds and compositions for delivering active agents
BR9808843A (pt) Derivados de quinolinona 1,8-anelados inibidores da farnesil transferase substituìdos com imidazóis ligados em n ou em c
NO931766D0 (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
Diel Bisphosphonates in the prevention of bone metastases: current evidence
DK0683762T3 (da) Acylfulven-analoger som antitumormidler
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
DK1608349T3 (da) Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel
IT1255723B (it) Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
IS2387B (is) Æxliseyðandi efni
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
BR9915390A (pt) Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas
BR9709556A (pt) Dihidrobenzopirano e compostos a ele relacionados úteis como agentes antiflamatórios
Hattori et al. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth
BR0012502A (pt) Inibidores da expressão do gene para interleucina 5
KR960705791A (ko) 기억력 향상제로서 유용한 3-아릴-4-알킬 및 4,5-디알킬-4H-1,2,4-트리아졸(3Aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles useful as memory enhancers)
BR9610077A (pt) Utilização de um composto e associação